|Home | About Dr. Robbins | Archived Articles | Headache Books | Topic Index|
A New Formulation of Dihydroergotamine (DHE) is Effective for Sustaining Relief in the Acute Treatment of Migraine (July 2003)
Repetitive intravenous administration of valproate sodium in intractable migraine: comparison with intravenous dihydroergotamine (DHE) (Posted Nov 2000)
A Retrospective Study of Self-Administered Subcutaneous Dihydroergotamine in the Outpatient Treatment of Chronic Daily Headache Associated with Medication Overuse (Posted June 2000)
DHE: An Old Drug Made New (Posted Jan 1999)
A Retrospective Study of Self-Administered Subcutaneous Dihydroergotamine in the Outpatient Treatment of Chronic Daily Headache Associated with Medication Overuse
DHE: An Old Drug Made New
The following is the abstract taken from: Oliver RL. DHE: An old drug made new. Amer J Pain Mgmt 1999; 9:35-38.
Dihydroergotamine (DHE) has been available for over 50 years for the abortion of migraine and prior to that, there was ergotamine tartrate, a similar medicine but one with more adverse effects. In recent years, additional methods of administration have made DHE more usable. Each form (intravenous, intramuscular, subcutaneous, and intranasal) has advantages and disadvantages. Intravenous administration is considered to be the best way to treat chronic daily headache and status post migranosus, inpatient or outpatient. Intramuscular and subcutaneous administration of DHE are the best ways to get quick headache relief without requiring the patient to be hospitalized, in most cases.
Intranasal (nasal spray) is the most patient-friendly route of administration and is often as efficacious as the other forms of DHE, while still being as effective and safe for abortion of migraine as new medications currently being marketed. Whatever the administration form, dihydroergotamine has proven to still be an effective agent for the abortion of migraine.
Copyright © 2002- Lawrence Robbins, MD